Pharmacogenetics and stroke

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Genetic variations have been shown to influence drug metabolism, risk of adverse drug events, and pharmacodynamic responses for many drugs routinely used to treat patients with stroke or at risk for stroke. Examples include clopidogrel, statins, antihypertensive medications, and coumadin. Further validation studies are needed to assess the clinical utility of selecting drugs and doses based on genetic tests. Physicians, pharmaceutical companies, regulatory agencies, and health insurers continue to grapple with how best to translate this burgeoning field into effective individualized medicine.

Original languageEnglish (US)
Pages (from-to)3641-3645
Number of pages5
JournalStroke
Volume40
Issue number11
DOIs
StatePublished - Nov 2009

Fingerprint

Pharmacogenetics
Stroke
clopidogrel
Pharmaceutical Preparations
Occupational Health Physicians
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Insurance Carriers
Precision Medicine
Validation Studies
Warfarin
Drug-Related Side Effects and Adverse Reactions
Antihypertensive Agents
Health

Keywords

  • Cerebral infarction
  • Genetics
  • Genomics
  • Ischemic stroke
  • Pharmacogenomics
  • Pharmacology
  • Prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Pharmacogenetics and stroke. / Meschia, James F.

In: Stroke, Vol. 40, No. 11, 11.2009, p. 3641-3645.

Research output: Contribution to journalArticle

Meschia, James F. / Pharmacogenetics and stroke. In: Stroke. 2009 ; Vol. 40, No. 11. pp. 3641-3645.
@article{fe76dea431ad4ec5b00c1fb042afe04f,
title = "Pharmacogenetics and stroke",
abstract = "Genetic variations have been shown to influence drug metabolism, risk of adverse drug events, and pharmacodynamic responses for many drugs routinely used to treat patients with stroke or at risk for stroke. Examples include clopidogrel, statins, antihypertensive medications, and coumadin. Further validation studies are needed to assess the clinical utility of selecting drugs and doses based on genetic tests. Physicians, pharmaceutical companies, regulatory agencies, and health insurers continue to grapple with how best to translate this burgeoning field into effective individualized medicine.",
keywords = "Cerebral infarction, Genetics, Genomics, Ischemic stroke, Pharmacogenomics, Pharmacology, Prevention",
author = "Meschia, {James F}",
year = "2009",
month = "11",
doi = "10.1161/STROKEAHA.109.562231",
language = "English (US)",
volume = "40",
pages = "3641--3645",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Pharmacogenetics and stroke

AU - Meschia, James F

PY - 2009/11

Y1 - 2009/11

N2 - Genetic variations have been shown to influence drug metabolism, risk of adverse drug events, and pharmacodynamic responses for many drugs routinely used to treat patients with stroke or at risk for stroke. Examples include clopidogrel, statins, antihypertensive medications, and coumadin. Further validation studies are needed to assess the clinical utility of selecting drugs and doses based on genetic tests. Physicians, pharmaceutical companies, regulatory agencies, and health insurers continue to grapple with how best to translate this burgeoning field into effective individualized medicine.

AB - Genetic variations have been shown to influence drug metabolism, risk of adverse drug events, and pharmacodynamic responses for many drugs routinely used to treat patients with stroke or at risk for stroke. Examples include clopidogrel, statins, antihypertensive medications, and coumadin. Further validation studies are needed to assess the clinical utility of selecting drugs and doses based on genetic tests. Physicians, pharmaceutical companies, regulatory agencies, and health insurers continue to grapple with how best to translate this burgeoning field into effective individualized medicine.

KW - Cerebral infarction

KW - Genetics

KW - Genomics

KW - Ischemic stroke

KW - Pharmacogenomics

KW - Pharmacology

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=71049160077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049160077&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.109.562231

DO - 10.1161/STROKEAHA.109.562231

M3 - Article

C2 - 19762696

AN - SCOPUS:71049160077

VL - 40

SP - 3641

EP - 3645

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 11

ER -